"10.1371_journal.pone.0098955","plos one","2014-06-04T00:00:00Z","Sofie H Mooij; Hein J Boot; Arjen G C L Speksnijder; Chris J L M Meijer; Audrey J King; Dominique W M Verhagen; Henry J C de Vries; Wim G V Quint; Anco Molijn; Maurits N C de Koning; Marianne A B van der Sande; Maarten F Schim van der Loeff","Cluster of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Department of Pathology, Vrije Universiteit-University Medical Center, Amsterdam, the Netherlands; Department of Internal Medicine, Jan van Goyen Medical Center, Amsterdam, the Netherlands; Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; DDL Diagnostic Laboratory, Rijswijk, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands","Conceived and designed the experiments: MSvdL MvdS HB CM AM WQ MdK. Performed the experiments: AK AS MdK SM. Analyzed the data: SM MSvdL MdK. Contributed reagents/materials/analysis tools: AS DV HdV SM AM WQ MdK. Wrote the paper: SM MSvdL. Contributed to discussion and revision of the manuscript: SM AS CM AK DV HdV WQ AM MdK MvdS MSvdL.","Sanofi Pasteur MSD provided funding towards this study. M. Schim van der Loeff participated in a Merck-funded investigator-initiated study on Gardasil Â®. M. Schim van der Loeff and C. Meijer are co-investigators on an HPV vaccine trial of Sanofi-Pasteur MSD (EudraCT Number:2013-003399-10). W. Quint, A. Molijn, and M. de Koning are employees of DDL, a diagnostic testing laboratory that participated in the development of the HPV tests used in this study. C. Meijer is shareholder of Self-Screen, a spinoff company from Vrije Universiteit-University Medical Center, which makes diagnostic tests for cervical cancer. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","06","Sofie H Mooij","SHM",12,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
